A major hurdle in EV-based therapies is the “yield gap” — standard lab protocols simply cannot produce the volume of extracellular vesicles (EVs) required for clinical applications. However, scale-up could impact the quality and potency of therapeutic EVs.
In our latest co-authored study published in 𝗦𝘁𝗲𝗺 𝗖𝗲𝗹𝗹𝘀 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲, the teams at Exosomica, the Innovative Medicine Centre, the University of Latvia, alongside TAmiRNA scientists, addressed this challenge head-on. Together, we applied deep molecular fingerprinting and in vivo potency studies to validate a new large-scale production protocol for Parkinson’s Disease (PD) therapies.
By leveraging our specialized transcriptomic and proteomic pipelines, we analyzed how production and purification methods shape the EV “message”:
✅ 𝟯𝗗 𝘃𝘀. 𝟮𝗗 𝗖𝗼𝗺𝗽𝗮𝗿𝗶𝘀𝗼𝗻: Our analysis revealed that while mRNA and proteomic content remained stable, culture conditions (3D bioreactors vs. 2D flasks) significantly influenced the 𝗺𝗶𝗥𝗡𝗔 𝗽𝗿𝗼𝗳𝗶𝗹𝗲𝘀 of the EVs.
✅ 𝗨𝗹𝘁𝗿𝗮𝗰𝗲𝗻𝘁𝗿𝗶𝗳𝘂𝗴𝗮𝘁𝗶𝗼𝗻 𝘃𝘀. 𝗧𝗙𝗙-𝗦𝗘𝗖: protein and miRNA profiles change significantly depending on the method of purification, while the mRNA cargo remained stable.
✅ 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗙𝗶𝗻𝗴𝗲𝗿𝗽𝗿𝗶𝗻𝘁𝗶𝗻𝗴 𝗮𝗻𝗱 𝗙𝘂𝗻𝗰𝘁𝗶𝗼𝗻𝗮𝗹 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀: We identified enrichment in miRNAs associated with 𝗮𝗻𝘁𝗶-𝗼𝘅𝗶𝗱𝗮𝘁𝗶𝘃𝗲 and 𝗮𝗻𝘁𝗶-𝗶𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗼𝗿𝘆 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗲𝘀, providing a molecular basis for the therapeutic effects seen in vivo.
✅ 𝗣𝗿𝗼𝘃𝗲𝗻 𝗘𝗳𝗳𝗶𝗰𝗮𝗰𝘆: The study demonstrated that EVs produced via this new 463-fold scale-up protocol were just as effective as standard methods in improving gait and cognitive functions in PD models.
This research proves that with the right scale-up strategy and rigorous molecular validation, we can produce the high-quality, high-volume EV treatments needed for the future of regenerative neuro-medicine.
Congratulations to the authors on this impressive achievement! 👏
